高出血风险的抗血栓治疗,第二部分:非心脏皮肤干预措施
Mattia Galli1, Felice Gragnano2, Martina Berteotti3
1Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.
对于非心脏皮肤干预的抗血栓治疗需要仔细考虑,特别是在高出血风险患者中. 心脏干预的证据可能不直接适用,需要量身定制的方法.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 血管医学 血管医学
背景情况:
- 对于穿皮干预措施,抗血栓管理方面已经取得了重大进展.
- 目前的证据主要来自心脏干预,往往导致推断到非心脏手术.
- 心脏和非心脏环境之间的患者风险概况和干预类型的差异可能会影响抗血栓治疗的结果.
研究的目的:
- 审查和评估在接受非心脏皮肤干预手术的患者中对抗血栓治疗的现有证据.
- 在此背景下,强调高出血风险个体面临的具体挑战和考虑.
- 强调风险分层在指导抗血栓治疗临床决策中的重要性.
主要方法:
- 对现有文献进行系统审查.
- 关于抗血栓策略的证据评估.
- 专注于涉及非心脏穿皮干预的研究.
- 对高出血风险患者群体的结局分析.
主要成果:
- 大多数抗血栓性证据来自心脏干预.
- 非心脏干预经常涉及高出血风险患者.
- 将心脏病治疗方案推算到非心脏病的环境中可能会引起安全性和疗效方面的担忧.
结论:
- 与心脏手术相比,非心脏皮肤干预的抗血栓治疗需要不同的考虑.
- 在接受非心脏干预的患者中,高出血风险显著影响结果.
- 风险分层对于优化这一群体抗血栓治疗决策至关重要.
更多相关视频
06:10Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
09:02Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Acute Coronary Syndrome IV: Interprofessional Care
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
